Aclarion, Inc. (NASDAQ: ACON) Stock Competitors & Peer Comparison

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, VEEV has a market cap of 30.3B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while VEEV trades at $186.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas VEEV's P/E ratio is 22.37. In terms of profitability, ACON's ROE is -0.54%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, ACON is more volatile compared to VEEV. This indicates higher risk in terms of short-term price fluctuations for ACON.Check VEEV's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, GEHC has a market cap of 27.6B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while GEHC trades at $60.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas GEHC's P/E ratio is 13.29. In terms of profitability, ACON's ROE is -0.54%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ACON is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ACON.Check GEHC's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas GEHCV's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, ACON is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for ACON.Check GEHCV's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, BTSG has a market cap of 14.3B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while BTSG trades at $72.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas BTSG's P/E ratio is 58.80. In terms of profitability, ACON's ROE is -0.54%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to BTSG. This indicates higher risk in terms of short-term price fluctuations for ACON.Check BTSG's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, BTSGU has a market cap of 14.2B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while BTSGU trades at $238.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas BTSGU's P/E ratio is 215.44. In terms of profitability, ACON's ROE is -0.54%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for ACON.Check BTSGU's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SGFY's P/E ratio is 70.91. In terms of profitability, ACON's ROE is -0.54%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, ACON is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for ACON.Check SGFY's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, HQY has a market cap of 7.9B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while HQY trades at $94.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas HQY's P/E ratio is 22.11. In terms of profitability, ACON's ROE is -0.54%, compared to HQY's ROE of +0.11%. Regarding short-term risk, ACON is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for ACON.Check HQY's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, TEM has a market cap of 7.5B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while TEM trades at $42.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas TEM's P/E ratio is -85.38. In terms of profitability, ACON's ROE is -0.54%, compared to TEM's ROE of -0.70%. Regarding short-term risk, ACON is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for ACON.Check TEM's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas RCM's P/E ratio is -102.21. In terms of profitability, ACON's ROE is -0.54%, compared to RCM's ROE of +0.00%. Regarding short-term risk, ACON is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for ACON.Check RCM's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, TXG has a market cap of 5.9B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while TXG trades at $46.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas TXG's P/E ratio is -272.18. In terms of profitability, ACON's ROE is -0.54%, compared to TXG's ROE of -0.03%. Regarding short-term risk, ACON is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ACON.Check TXG's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, HNGE has a market cap of 5.8B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while HNGE trades at $74.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas HNGE's P/E ratio is 38.12. In terms of profitability, ACON's ROE is -0.54%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, ACON is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for ACON.Check HNGE's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, DOCS has a market cap of 3.8B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while DOCS trades at $20.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas DOCS's P/E ratio is 13.35. In terms of profitability, ACON's ROE is -0.54%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, ACON is more volatile compared to DOCS. This indicates higher risk in terms of short-term price fluctuations for ACON.Check DOCS's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ONEM's P/E ratio is -7.77. In terms of profitability, ACON's ROE is -0.54%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, ACON is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for ACON.Check ONEM's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, PRVA has a market cap of 3.2B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while PRVA trades at $25.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas PRVA's P/E ratio is 159.38. In terms of profitability, ACON's ROE is -0.54%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, ACON is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for ACON.Check PRVA's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, PGNY has a market cap of 2.4B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while PGNY trades at $31.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas PGNY's P/E ratio is 22.77. In terms of profitability, ACON's ROE is -0.54%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, ACON is more volatile compared to PGNY. This indicates higher risk in terms of short-term price fluctuations for ACON.Check PGNY's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, HTFL has a market cap of 2.1B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while HTFL trades at $24.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas HTFL's P/E ratio is -12.00. In terms of profitability, ACON's ROE is -0.54%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, ACON is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for ACON.Check HTFL's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, WGS has a market cap of 1.8B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while WGS trades at $59.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas WGS's P/E ratio is 69.53. In terms of profitability, ACON's ROE is -0.54%, compared to WGS's ROE of -0.28%. Regarding short-term risk, ACON is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for ACON.Check WGS's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas NXGN's P/E ratio is -266.00. In terms of profitability, ACON's ROE is -0.54%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, ACON is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for ACON.Check NXGN's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, TDOC has a market cap of 1.6B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while TDOC trades at $8.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas TDOC's P/E ratio is -9.75. In terms of profitability, ACON's ROE is -0.54%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, ACON is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for ACON.Check TDOC's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas AGTI's P/E ratio is -71.79. In terms of profitability, ACON's ROE is -0.54%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, ACON is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for ACON.Check AGTI's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, OMDA has a market cap of 1.2B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while OMDA trades at $20.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas OMDA's P/E ratio is 293.29. In terms of profitability, ACON's ROE is -0.54%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, ACON is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for ACON.Check OMDA's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CERT has a market cap of 1.2B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CERT trades at $7.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CERT's P/E ratio is 19.26. In terms of profitability, ACON's ROE is -0.54%, compared to CERT's ROE of -0.01%. Regarding short-term risk, ACON is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for ACON.Check CERT's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, GDRX has a market cap of 1B. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while GDRX trades at $2.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas GDRX's P/E ratio is 8.97. In terms of profitability, ACON's ROE is -0.54%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, ACON is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for ACON.Check GDRX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CCLDO's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CCLDO's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, HSTM has a market cap of 792.8M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while HSTM trades at $27.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas HSTM's P/E ratio is 35.70. In terms of profitability, ACON's ROE is -0.54%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, ACON is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for ACON.Check HSTM's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, PHR has a market cap of 632.6M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while PHR trades at $10.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas PHR's P/E ratio is 36.55. In terms of profitability, ACON's ROE is -0.54%, compared to PHR's ROE of +0.03%. Regarding short-term risk, ACON is less volatile compared to PHR. This indicates lower risk in terms of short-term price fluctuations for ACON.Check PHR's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, ACON is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for ACON.Check MPLN-WT's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ACCD's P/E ratio is -3.08. In terms of profitability, ACON's ROE is -0.54%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, ACON is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for ACON.Check ACCD's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SHCR's P/E ratio is -3.76. In terms of profitability, ACON's ROE is -0.54%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, ACON is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for ACON.Check SHCR's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, WGSWW has a market cap of 514.5M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas WGSWW's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, ACON is less volatile compared to WGSWW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check WGSWW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, EVH has a market cap of 474.7M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while EVH trades at $4.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas EVH's P/E ratio is 422.00. In terms of profitability, ACON's ROE is -0.54%, compared to EVH's ROE of -0.78%. Regarding short-term risk, ACON is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for ACON.Check EVH's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, NRC has a market cap of 474.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while NRC trades at $21.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas NRC's P/E ratio is 25.66. In terms of profitability, ACON's ROE is -0.54%, compared to NRC's ROE of +0.57%. Regarding short-term risk, ACON is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for ACON.Check NRC's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SLGC's P/E ratio is -3.04. In terms of profitability, ACON's ROE is -0.54%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, ACON is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SLGC's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, ACON's ROE is -0.54%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, ACON is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SLGCW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas TBRG's P/E ratio is 9.37. In terms of profitability, ACON's ROE is -0.54%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, ACON is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for ACON.Check TBRG's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SOPH has a market cap of 393.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SOPH trades at $5.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SOPH's P/E ratio is -11.00. In terms of profitability, ACON's ROE is -0.54%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, ACON is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SOPH's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MPLN's P/E ratio is -0.23. In terms of profitability, ACON's ROE is -0.54%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, ACON is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for ACON.Check MPLN's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SLP has a market cap of 370.9M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SLP trades at $18.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SLP's P/E ratio is 20.84. In terms of profitability, ACON's ROE is -0.54%, compared to SLP's ROE of +0.06%. Regarding short-term risk, ACON is more volatile compared to SLP. This indicates higher risk in terms of short-term price fluctuations for ACON.Check SLP's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CTEV has a market cap of 369.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CTEV trades at $21.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CTEV's P/E ratio is -1.66. In terms of profitability, ACON's ROE is -0.54%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, ACON is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for ACON.Check CTEV's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas TRHC's P/E ratio is -4.27. In terms of profitability, ACON's ROE is -0.54%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, ACON is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for ACON.Check TRHC's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SY has a market cap of 253.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SY trades at $1.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SY's P/E ratio is -5.85. In terms of profitability, ACON's ROE is -0.54%, compared to SY's ROE of -0.16%. Regarding short-term risk, ACON is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SY's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SMFR's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, ACON is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SMFR's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SPOK has a market cap of 221.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SPOK trades at $10.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SPOK's P/E ratio is 17.65. In terms of profitability, ACON's ROE is -0.54%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, ACON is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for ACON.Check SPOK's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, AMWL has a market cap of 179.4M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while AMWL trades at $10.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas AMWL's P/E ratio is -2.07. In terms of profitability, ACON's ROE is -0.54%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, ACON is more volatile compared to AMWL. This indicates higher risk in terms of short-term price fluctuations for ACON.Check AMWL's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, HCAT has a market cap of 153.7M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while HCAT trades at $2.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas HCAT's P/E ratio is 10.40. In terms of profitability, ACON's ROE is -0.54%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, ACON is less volatile compared to HCAT. This indicates lower risk in terms of short-term price fluctuations for ACON.Check HCAT's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CPSI's P/E ratio is -183.80. In terms of profitability, ACON's ROE is -0.54%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, ACON is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for ACON.Check CPSI's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, OPRX has a market cap of 117.1M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while OPRX trades at $6.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas OPRX's P/E ratio is 5.72. In terms of profitability, ACON's ROE is -0.54%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, ACON is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for ACON.Check OPRX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas AUGX's P/E ratio is -4.99. In terms of profitability, ACON's ROE is -0.54%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, ACON is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for ACON.Check AUGX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CCLD has a market cap of 94.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CCLD trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CCLD's P/E ratio is 8.22. In terms of profitability, ACON's ROE is -0.54%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to CCLD. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CCLD's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, DH has a market cap of 72.4M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while DH trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas DH's P/E ratio is 2.64. In terms of profitability, ACON's ROE is -0.54%, compared to DH's ROE of -0.67%. Regarding short-term risk, ACON is more volatile compared to DH. This indicates higher risk in terms of short-term price fluctuations for ACON.Check DH's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas FORA's P/E ratio is -24.11. In terms of profitability, ACON's ROE is -0.54%, compared to FORA's ROE of -0.17%. Regarding short-term risk, ACON is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for ACON.Check FORA's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CCLDP's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CCLDP's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ONMD has a market cap of 35M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ONMD trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ONMD's P/E ratio is -4.10. In terms of profitability, ACON's ROE is -0.54%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, ACON is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for ACON.Check ONMD's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SNCE's P/E ratio is -0.27. In terms of profitability, ACON's ROE is -0.54%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, ACON is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for ACON.Check SNCE's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas AKLI's P/E ratio is -0.71. In terms of profitability, ACON's ROE is -0.54%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, ACON is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for ACON.Check AKLI's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SHLT's P/E ratio is -3.87. In terms of profitability, ACON's ROE is -0.54%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, ACON is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for ACON.Check SHLT's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, ACON's ROE is -0.54%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, ACON is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SHCRW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, EUDA has a market cap of 28M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while EUDA trades at $14.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas EUDA's P/E ratio is -28.30. In terms of profitability, ACON's ROE is -0.54%, compared to EUDA's ROE of +0.70%. Regarding short-term risk, ACON is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for ACON.Check EUDA's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ONMDW has a market cap of 27.8M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ONMDW's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, ACON is less volatile compared to ONMDW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check ONMDW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas STRM's P/E ratio is -2.40. In terms of profitability, ACON's ROE is -0.54%, compared to STRM's ROE of -0.32%. Regarding short-term risk, ACON is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for ACON.Check STRM's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas RNLX's P/E ratio is -0.33. In terms of profitability, ACON's ROE is -0.54%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, ACON is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for ACON.Check RNLX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas LIFW's P/E ratio is -0.02. In terms of profitability, ACON's ROE is -0.54%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, ACON is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for ACON.Check LIFW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, BEATW has a market cap of 15.9M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while BEATW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas BEATW's P/E ratio is -0.04. In terms of profitability, ACON's ROE is -0.54%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, ACON is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check BEATW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas BBLN's P/E ratio is -0.04. In terms of profitability, ACON's ROE is -0.54%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, ACON is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for ACON.Check BBLN's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ETAO's P/E ratio is -0.01. In terms of profitability, ACON's ROE is -0.54%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, ACON is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for ACON.Check ETAO's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, BFRG has a market cap of 7.1M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while BFRG trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas BFRG's P/E ratio is -1.12. In terms of profitability, ACON's ROE is -0.54%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, ACON is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for ACON.Check BFRG's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SCNX has a market cap of 5.7M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SCNX trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SCNX's P/E ratio is -0.15. In terms of profitability, ACON's ROE is -0.54%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, ACON is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SCNX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas UPH's P/E ratio is -0.07. In terms of profitability, ACON's ROE is -0.54%, compared to UPH's ROE of -1.05%. Regarding short-term risk, ACON is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for ACON.Check UPH's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, ACON is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for ACON.Check UPH-WT's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MGRX has a market cap of 5.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MGRX trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MGRX's P/E ratio is -0.39. In terms of profitability, ACON's ROE is -0.54%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, ACON is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for ACON.Check MGRX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas PEAR's P/E ratio is -0.08. In terms of profitability, ACON's ROE is -0.54%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, ACON is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for ACON.Check PEAR's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas PEARW's P/E ratio is -0.00. In terms of profitability, ACON's ROE is -0.54%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, ACON is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check PEARW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas OTRK's P/E ratio is -0.02. In terms of profitability, ACON's ROE is -0.54%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, ACON is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for ACON.Check OTRK's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, HCTI has a market cap of 1.9M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while HCTI trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas HCTI's P/E ratio is -0.21. In terms of profitability, ACON's ROE is -0.54%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, ACON is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for ACON.Check HCTI's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CMAX's P/E ratio is -0.00. In terms of profitability, ACON's ROE is -0.54%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, ACON is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CMAX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, VSEE has a market cap of 1.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while VSEE trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas VSEE's P/E ratio is -0.15. In terms of profitability, ACON's ROE is -0.54%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, ACON is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for ACON.Check VSEE's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, VSEEW has a market cap of 1.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, ACON's ROE is -0.54%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, ACON is more volatile compared to VSEEW. This indicates higher risk in terms of short-term price fluctuations for ACON.Check VSEEW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, ACON is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for ACON.Check LIFWZ's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, EUDAW has a market cap of 922.5K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while EUDAW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, ACON's ROE is -0.54%, compared to EUDAW's ROE of +0.70%. Regarding short-term risk, ACON is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check EUDAW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, WORX has a market cap of 629.5K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while WORX trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas WORX's P/E ratio is -0.69. In terms of profitability, ACON's ROE is -0.54%, compared to WORX's ROE of -0.65%. Regarding short-term risk, ACON is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for ACON.Check WORX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, ACON is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for ACON.Check MSPRZ's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas KERNW's P/E ratio is -0.00. In terms of profitability, ACON's ROE is -0.54%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, ACON is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check KERNW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas KERN's P/E ratio is -0.01. In terms of profitability, ACON's ROE is -0.54%, compared to KERN's ROE of -0.17%. Regarding short-term risk, ACON is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for ACON.Check KERN's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas LIFWW's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, ACON is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for ACON.Check LIFWW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ZCMD has a market cap of 48.6K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ZCMD trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ZCMD's P/E ratio is -0.05. In terms of profitability, ACON's ROE is -0.54%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, ACON is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for ACON.Check ZCMD's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CMAXW's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, ACON is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CMAXW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, ACONW has a market cap of 11.9K. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while ACONW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas ACONW's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, ACON is less volatile compared to ACONW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check ACONW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CSLT's P/E ratio is -37.27. In terms of profitability, ACON's ROE is -0.54%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, ACON is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CSLT's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CERN has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CERN's P/E ratio is 55.84. In terms of profitability, ACON's ROE is -0.54%, compared to CERN's ROE of +0.14%. Regarding short-term risk, ACON is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CERN's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas SMFRW's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to SMFRW's ROE of -0.28%. Regarding short-term risk, ACON is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for ACON.Check SMFRW's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas AFFX's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, ACON is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for ACON.Check AFFX's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MTBCO's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for ACON.Check MTBCO's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MSPRV's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to MSPRV's ROE of N/A. Regarding short-term risk, ACON is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for ACON.Check MSPRV's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CNVY's P/E ratio is -71.50. In terms of profitability, ACON's ROE is -0.54%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, ACON is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CNVY's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MTBCP's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, ACON is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for ACON.Check MTBCP's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas MTBC's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, ACON is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for ACON.Check MTBC's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas CHNG's P/E ratio is -152.72. In terms of profitability, ACON's ROE is -0.54%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, ACON is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for ACON.Check CHNG's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, IMS has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas IMS's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to IMS's ROE of +0.27%. Regarding short-term risk, ACON is more volatile compared to IMS. This indicates higher risk in terms of short-term price fluctuations for ACON.Check IMS's competition here

Aclarion, Inc. (NASDAQ: ACON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACON stands at 1.3M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, ACON is priced at $2.42 on the NASDAQ, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACON currently has a P/E ratio of -0.23, whereas KURIU's P/E ratio is N/A. In terms of profitability, ACON's ROE is -0.54%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, ACON is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for ACON.Check KURIU's competition here